Skip to main content

Table 2 Participants who used and had their regimens changed and the duration of use

From: Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon

Antiretroviral therapy regimens Participants who ever received regimen Participants who had their regimen changed (%)a Median ART duration in months (IQR) Range of ART duration in months
Zidovudine-lamivudine-nevirapine 83 43 (52.4%) 9 (7–14) 1–47
Tenofovir-lamivudine-nevirapine 65 20 (30.8%) 2 (2–3) 1–24
Stavudine-lamivudine-nevirapine 53 53 (100%) 58 (37–80) 8–110
Zidovudine-lamivudine-efavirenz 15 10 (66.7%) 13 (2–24) 1–69
Tenofovir-lamivudine-efavirenz 9 2 (22.2%) 9 (7–14) 1–47
Tenofovir-emcitrabine-nevirapine 2 0 (0.0%) 3 (2–4) 2–4
Tenofovir-emcitrabine-efavirenz 1 1 (100%) 29 (29–29) 29
  1. aPercentages in parenthesis correspond to the number of participants who had their regimen changed as a proportion of the number of participants who ever received that regimen